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SIRT3Lipid peroxidation plays a critical role in cardiovascular diseases. Aldehydes are the major end products of
lipid peroxidation and can be metabolized into less reactive chemical species by aldehyde dehydrogenase 2
(ALDH2). However, ALDH2 dehydrogenase activity can be affected by many factors including reactive oxygen
species. To elucidate how reactive oxygen species inhibit ALDH2 dehydrogenase activity, we stimulated
human aortic endothelial cells (HAECs) with oxidized low-density lipoproteins (ox-LDL) and performed a
myocardial ischemia–reperfusion model. Ox-LDL treatment and ischemia–reperfusion injury inhibited
ALDH2 dehydrogenase activity. Poly(ADP-ribose) polymerase (PARP) was activated by ox-LDL stimulation
and ischemia–reperfusion injury and PARP inhibition partly restored ALDH2 dehydrogenase activity in
ox-LDL treated HAECs and ischemia–reperfusion rat hearts. SIRT3 was upregulated by ox-LDL stimulation
and ischemia–reperfusion injury and downregulated by PARP inhibition. Using siRNA to knock down
SIRT3, we demonstrated that SIRT3 mediated deacetylation decreased ALDH2 dehydrogenase activity and
PARP inhibition partly restored ALDH2 dehydrogenase activity through preventing SIRT3 expression and sub-
sequently preserving ALDH2 acetylation.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Lipid peroxidation plays a critical role in atherosclerosis [1], myocar-
dial hypertrophy [2], heart failure [3] and other cardiovascular diseases
[4]. Aldehydes are the major end products of lipid peroxidation and
react with nucleic acids and proteins to generate various adducts that
result in DNA damage/deletion/mutation and the inactivation of pro-
teins [4–6]. Consequently, these aldehydes negatively affect normal
functions ofDNA and proteins, evendirectly promote cell or tissue dam-
age [6]. Aldehydes can be metabolized into less reactive chemical
species by glutathione S-transferases, aldo-keto reductases, aldehyde
dehydrogenases, cytochromes P450 and phospholipase [4,6].d, Qilu Hospital of Shandong
en919085@126.com (Y. Chen).
rights reserved.Aldehyde dehydrogenases (ALDHs) are a superfamily that consists
of 19 distinct ALDH genes in the human genome [7]. ALDHs can con-
vert toxic aldehydes to less toxic carboxylates. Among them, ALDH2
displays the highest afﬁnity for acetaldehyde [4]. Moreover, ALDH2
can detoxify other aromatic and aliphatic aldehydes, including
4-hydroxy-2-nonenal (4HNE), which is a highly cytotoxic aldehyde.
ALDH2 is a NAD+-dependent enzyme that primarily localizes to the
mitochondria [5]. ALDH2 plays a critical role in many cardiovascular
diseases, including coronary artery disease [8], ischemia–reperfusion
injury [9,10], diabetic cardiomyopathy [11,12], cardiac dysfunction
[13] and myocardial hypertrophy [14]. However, the dehydrogenase
activity of ALDH2 can be inhibited by many factors. ALDH2 dehydro-
genase activity is regulated by several signal molecules, including
protein kinase Cε (PKCε) [9], c-Jun N-terminal kinase (JNK) [15] and
SIRT3 [16,17]. Moreover, ALDH2 dehydrogenase activity is redox
sensitive [18]. Reactive oxygen species (ROS) and reactive nitrogen
species (RNS) can also inhibit ALDH2 dehydrogenase activity. However,
the mechanism how ROS decrease ALDH2 activity remains elusive.
Poly(ADP-ribose) polymerase (PARP) is an enzyme family that cata-
lyzes the cleavage of nicotinamide adenine dinucleotide (NAD+) into
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polymers on glutamic acid residues of a number of target proteins
[19]. DNA strand breaks induced by ROS lead to the activation of
PARP. PARP overactivation results in the rapid depletion of intracellular
NAD+ [20]. ROS inhibit ALDH2 activation but activate PARP. PARP
activation depletes intracellular NAD+ and ALDH2 is a mitochondrial
NAD+-dependent enzyme. Therefore, we speculate that PARP activa-
tion may participate in the ROS-induced inhibition of ALDH2 dehydro-
genase activity.
In the present study, we examined the effect of oxidized low-
density lipoproteins (ox-LDL) on ALDH2 activity in human aortic en-
dothelial cells (HAECs) and the effect of ischemia–reperfusion injury
on ALDH2 activity in rat hearts. We found that ox-LDL and ischemia
reperfusion injury obviously reduced ALDH2 activity and PARP inhibi-
tion partly restored ALDH2 activity in HAECs and rat hearts. Further-
more, SIRT3 might be the downstream molecule through which PARP
regulates ALDH2 dehydrogenase activity.
2. Materials and methods
2.1. Materials
Ox-LDL was purchased from Yuanyuan Biotech (Guangzhou, China).
3, 4-Dihydro-5[4-(1-piperindinyl)butoxy]-1(2H)-isoquinoline (DPQ),
apocynin, rotenone, Nω-nitro-L-arginine methyl ester hydrochloride
(L-NAME), allopurinol and N-acetyl-L-cysteine (NAC) were purchased
from Sigma-Aldrich (Louis, MO, USA). The following primary antibodies
were used: anti-ALDH2 and anti-β-actin were purchased from Santa
Cruz (CA, USA), anti-poly(ADP-ribose) (PAR) was from Alexis (San
Diego, CA, USA), anti-SIRT-3 and anti-acetyl lysine antibody were from
Cell Signaling Technology (Danvers, MA, USA), and anti-gp91phox,
anti-GAPDH and anti-COX IV antibody were from abcam (San Francisco,
CA, USA). All secondary antibodies were purchased from Cell Signaling
Technology.
2.2. Cell culture
HAECs purchased from the American Type Culture Collection (ATCC,
Rockville, MD, USA) were cultured in endothelial cell medium
(Sciencell, Carlsbad, CA, USA) containing 5% fetal bovine serum in a
humidiﬁed atmosphere with 5% CO2 and 95% air at 37 °C. Passages
3–5 of cells were used for experiments. HAECs were stimulated with
ox-LDL at different concentrations for different times. If necessary,
apocynin (500 μM), rotenone (5 μM), L-NAME (100 μM), allopurinol
(50 μM), NAC (10 mM) or DPQ (10 μM) was used to treat HAECs
1 hour before ox-LDL (100 μg/ml) stimulation.
2.3. Acute myocardial ischemia reperfusion model
A total of 40 male Wistar rats weighing approximately 250 g were
divided into 4 groups: control group; DPQ group; ischemia–reperfusion
(IR) group and IR+DPQ group. These rats were anesthetized with in-
traperitoneal 3% pentobarbital (45 mg/kg) and ventilated via a trache-
ostomy on a Harvard rodent respirator. Half of the rats were
intraperitoneally injectedwith 5 mg/kg DPQ 30 minutes before surgery.
The heart was exposed via a left thoracotomy. In the IR group and
IR+DPQ group, the proximal left anterior descending artery (LAD)
was ligated using a 7-0 prolene suture with a slipknot for 30 minutes
and the knot was then released allowing the heart to reperfuse for
120 minutes. To differentiate between ischemic and nonischemic
tissue, 1 ml of Evans blue dye (2% in PBS) was injected into the left
ventricular cavity to measure the myocardial ischemic area at risk.
The heart was removed and sectioned into 3-mm slices. 2, 3,
5-Triphenyltetrazolium chloride (TTC, Sigma-Aldrich) was used to as-
sess myocardial tissue viability and determine the myocardial infarct
size. The tissue slices were incubated in 1% TTC PBS solution at 37 °Cfor 20 minutes. Images of each slice were captured and the myocardial
area at risk and infract areawere quantiﬁed. All the animal experiments
were approved by the Animal Care and Use Committee of Shandong
University, in accordance with AAALAC guidelines.
2.4. ALDH2 activity assay
Mitochondria were isolated from HAECs with the Cell Mitochondria
Isolation Kit (Beyotime, Haimen, China) and from myocardial tissue
with the Tissue Mitochondrial Isolation Kit (Beyotime). Mitochondrial
purity was assessed by western blot analysis (Supplemental data).
Then, the protein concentration was determined with a BCA Protein
Assay Kit (Beyotime). ALDH2 dehydrogenase activity was determined
by the reaction rate of the conversion of NAD+ to NADH at 340 nm in
a Thermo Fisher Varioskan Flash spectral scanning multimode reader
(Thermo Fisher) with the Cell Acetaldehyde Dehydrogenase Assay Kit
(Genemed, Shanghai, China). The dehydrogenase activity of ALDH2
was expressed as nmol/mg protein/minute.
2.5. Western blotting
HAECs and myocardial tissue were lysed with RIPA Lysis Buffer
(Beyotime) containing 1 mM PMSF. Protein samples were separated
on 15% polyacrylamide gels and transferred onto polyvinylidene ﬂuo-
ride membranes. After blocking in 5% non-fat milk for 2 hours, the
membranes were incubated with primary antibodies against ALDH2,
β-actin and SIRT3 overnight at 4 °C. On the second day, after being
washed 3 times with TBST for 5 minutes, the membranes were incu-
bated with corresponding horseradish peroxidase-labeled secondary
antibodies and visualized with enhanced chemiluminescence sub-
strate (Millipore, Billerica, MA).
2.6. ROS assay
HAECs in 6-well plates were incubated with 100 μg/ml ox-LDL for
2 hours. After being washed twice with PBS, ROS were determined
with the Reactive Oxygen Species Kit (Beyotime). Brieﬂy, cells were
incubated with DCFH-DA at 37 °C for 20 minutes. Within cells,
DCFH reacted with ROS to produce ﬂuorescent DCF. The ROS level
was examined in a Thermo Fisher Varioskan Flash spectral scanning
multimode reader. For the ﬂuorescence detection of ROS, the wave-
length was 488 nm for excitation and 580 nm for emission.
2.7. Immunoﬂuorescence and immunohistochemistry
HAECs cultured on glass coverslips were ﬁxed in 4% paraformalde-
hyde for 20 minutes, and then permeabilized with 0.01% Triton X-100
for 5 minutes. After being blocked in 10% rabbit serum for 1 hour, the
cells were incubated with a primary antibody against PAR overnight
at 4 °C. On the second day, FITC-conjugated secondary antibody was
added to bind the primary antibody. Finally, images were captured
with a laser scanning confocal microscope. Rat hearts embedded in par-
afﬁn were cross-sectioned into 5-μm slices. After rehydration in PBS,
sectionswere incubatedwith a primary antibody against PAR overnight
at 4 °C and the appropriate biotinylated secondary antibody. Subse-
quently, a 3,3′-diaminobenzidine (DAB) Kit was used to visualize
the primary antibody. Images were analyzed using Image Pro-Plus
software.
2.8. NAD+ assay
A cellular NAD+ assay was performed with the NAD+/NADH
Assay Kit (Abcam, San Francisco, CA). The cells were washed with
cold PBS and extracted the cells with NADH/NAD+ Extraction Buffer
by freeze/thaw two cycles. After adding NADH developer for 2 hours
at room temperature, total NADt and NADH were detected at 450 nm
Fig. 1. Ox-LDL decreased ALDH2 dehydrogenase activity. HAECs were incubated with 100 μg/ml ox-LDL for different times or with different concentrations of ox-LDL for 2 hours.
A, ALDH2 activity in 100 μg/ml ox-LDL treated HAECs at different time points. B, The protein expression of ALDH2 in 100 μg/ml ox-LDL treated HAECs at different times was deter-
mined byWestern blotting. C, ALDH2 dehydrogenase activity in HAECs treated with different concentrations of ox-LDL for 2 hours. D, Protein expression of ALDH2 in HAECs treated
with different concentrations of ox-LDL for 2 hours. The data and blots represent means of 3 samples of duplicate determinations in 5 separate experiments. *Pb0.05 vs control;
**Pb0.01 vs control.
Fig. 2. Ox-LDL stimulation increased ROS generation and PARP activation in HAECs. A, HAECs were treated with apocynin (500 μM), rotenone (5 μM), L-NAME (100 μM), allopurinol
(50 μM) or NAC (10 mM) for 1 hour and then stimulated with or without 100 μg/ml ox-LDL for 2 hours. After incubation with DCFH-DA, ROS production was determined and the
relative mean DCF ﬂuorescence is presented compared with the control. B and C, HAECs were stimulated with 100 μg/ml ox-LDL for 2 hours with or without pretreatment with
10 mM NAC. PAR expression was determined by immunoﬂuorescence, and the relative expression was quantitatively analyzed, Bar=50 μm. n=5. *Pb0.01 vs control; #Pb0.01
vs ox-LDL treated group; ##Pb0.05 vs ox-LDL treated group.
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expressed as nmol/mg protein. The mitochondrial NAD+ level was
determined in isolated mitochondria with above kit.2.9. Immunoprecipitation
Cells and myocardial tissue were lysed in non-denaturing cell lysis
buffer containing protease inhibitors. Whole cell lysates were incu-
bated with an antibody against ALDH2 for 1 hour followed by protein
(A/G)-agarose beads (Santa Cruz Biotechnology) overnight. The
immunocomplexes were washed three times and resuspended in
RIPA buffer. Supernatants were subjected to SDS-PAGE and probed
for acetyl lysine and ALDH2.2.10. Knockdown of SIRT3 by siRNA interference
The SIRT3 siRNA used in this study was purchased from Gene
Pharma (Shanghai, China). The cells were transfected with negative
control siRNA or SIRT3 siRNA using Lipofectamine 2000 Transfection
Reagent (Invitrogen).2.11. Statistical analysis
Data are presented as means±standard error (S.E.M). Differences
between two groups were evaluated using a two-tailed Student's
t-test. One way ANOVA was used to analyze data from more than
two groups. A value of Pb0.05 was considered statistically signiﬁcant.Fig. 3. PARP activation was associated with the ox-LDL induced decrease in ALDH2 dehydr
pretreatment with 10 nM DPQ for 1 hour. A, Immunoﬂuorescence staining for PAR and cou
hydrogenase activity was partly restored by PARP inhibition, n=5. D, The protein expressi
ments. *Pb0.01 vs control; **Pb0.05; #Pb0.01 vs ox-LDL treated group; ##Pb0.05 vs ox-LD3. Results
3.1. Ox-LDL stimulation decreased ALDH2 dehydrogenase activity in HAECs
The effects of ox-LDL on ALDH2 dehydrogenase activity were
determined in cultured HAECs. Fig. 1A shows that a time-dependent
decrease in ALDH2 enzyme activity was induced by 100 μg/ml
ox-LDL. The maximum effect was observed at 2 hours (46.8% de-
crease vs. control, Pb0.01; Fig. 1A). The dose response of the ox-LDL
effect was also measured in HAECs at 2 hours. ALDH2 dehydrogenase
activity decreased gradually in a dose-dependent manner (Fig. 1C).
100 μg/ml ox-LDL effectively decreased ALDH2 dehydrogenase activ-
ity at 2 hours, therefore, this concentration was used for subsequent
experiments. No changes were found in ALDH2 protein expression
(Fig. 1B and D) in HAECs stimulated with ox-LDL at different time
points or different concentrations.
3.2. Ox-LDL treatment induced PARP activation by increasing the
intracellular ROS level in HAECs
To determine how ox-LDL decreases ALDH2 activity in HAECs, we
ﬁrst tested the effect of ox-LDL on intracellular ROS production in
HAECs. As expected, 100 μg/ml ox-LDL increased the ROS production
in HAECs at 2 hours (Fig. 2A). To determine the sources of ROS in
ox-LDL treated HAVECs, apocynin (500 μM, an inhibitor of NAPDH
oxidase), rotenone (5 μM, an inhibitor of mitochondrial electron
transport chain complex I), L-NAME (100 μM, an inhibitor of nitric
oxide synthase), and allopurinol (50 μM, an inhibitor of xanthine
oxidase) were used. As shown in Fig. 2A, apocynin signiﬁcantly re-
duced the ROS production induced by ox-LDL, indicating thatogenase activity. HAECs were treated with 100 μg/ml ox-LDL for 2 hours only or after
nterstaining with DAPI, Bar=50 μm. B, Relative expression of PAR, n=5. C, ALDH2 de-
on of ALDH2 was immunoblotted. The blot represents the results of 3 separate experi-
L treated group.
Fig. 4. The mitochondrial NAD+ level was not changed by PARP inhibition. HAECs were
treated with 100 μg/ml ox-LDL only for 2 hours or after pretreatment with 10 nM DPQ
for 1 hour. A, Cellular NAD+ levels were determined. n=5. B, Mitochondrial NAD+
levels were determined. n=5. *Pb0.01 vs control; #Pb0.01 vs ox-LDL treated group.
Fig. 5. PARP activation decreased ALDH2 acetylation by upregulating SIRT3 expression.
HAECs were stimulated with 100 μg/ml ox-LDL only for 2 hours or after pretreatment
with 10 nM DPQ for 1 hour. A, The protein expression of SIRT3 was visualized with
western blotting. B, ALDH2 acetylation was determined with immunoblotting.
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inhibitors rotenone and L-NAME also inhibited the ROS production
induced by ox-LDL stimulation. Therefore,mitochondria and uncoupled
endothelial nitric oxide synthase also contribute to increased ROS levels
in ox-LDL treated HAECs. Excessive production of ROS can cause oxida-
tive damage to DNA. PARP, a DNA damage sensor and signaling mole-
cule can be activated by recognizing single or double-stranded DNA
breaks [19]. Ox-LDL stimulation markedly activated PARP in HAECs
(Fig. 2B and C). Using NAC (10 mM), we found that excessive ROS
productionwas effectively blockedby this antioxidant in ox-LDL treated
HAECs (Fig. 2A).Moreover, NAC signiﬁcantly prevented PARP activation
induced by ox-LDL stimulation (Fig. 2B and C).
3.3. PARP inhibition partly prevented the ox-LDL induced inhibition of
ALDH2 dehydrogenase activity in HAECs
To determine whether there was any relationship between ALDH2
dehydrogenase activity and PARP activation, the PARP inhibitor DPQ
was used before ox-LDL stimulation. Pretreatment with DPQ effec-
tively blocked ox-LDL induced PARP activation (Fig. 3A and B), and in-
terestingly, ALDH2 activity was partly restored by PARP inhibition in
ox-LDL treated HAECs (Fig. 3C). However, PARP inhibition did not
change the protein expression of ALDH2 (Fig. 3D).
3.4. The effect of PARP inhibition on ALDH2 dehydrogenase activity was
not mediated by mitochondrial NAD+
PARP initiates an energy-consuming cycle by catalyzing the cleav-
age of NAD+ to nicotinamide and ADP-ribose and then transferring
ADP ribose units to a number of target proteins [19]. Thus, PARP acti-
vation induces NAD+ depletion within cells. In our study, consistent
with PARP activation, ox-LDL stimulation decreased cellular NAD+
levels in HAECs, and PARP inhibition with DPQ preserved the cellular
NAD+ levels (Fig. 4A). As ALDH2 is a mitochondrial NAD+-dependent
enzyme, we evaluated the effect of PARP inhibition on mitochondrial
NAD+ level. We found ox-LDL did not decrease the mitochondrial
NAD+ level compared with control and PARP inhibition did not
alter the mitochondrial NAD+ level compared with ox-LDL treated
HAECs (Fig. 4B). This ﬁnding indicated that PARP did not affect
ALDH2 dehydrogenase activity by regulating the mitochondrial
NAD+ level.
3.5. PARP inhibition preserved ALDH2 acetylation by decreasing
SIRT3 expression
Silent information regulator 2 (SIR2) is a family of proteins with
NAD+-dependent deacetylase activity [21]. Seven isoforms of the
mammalian SIR2 homolog, SIRT1-7, are expressed in mammals [22].
Recent studies indicated that SIRT3 regulates ALDH2 activity [16,17].
SIRT3 is located in mitochondria and plays a role in the deacetylation
of mitochondrial proteins [23]. Therefore, we evaluated the SIRT3
protein expression in ox-LDL treated HAECs. Accompanied by PARP
activation, ox-LDL increased SIRT3 protein expression and PARP inhi-
bition with DPQ inhibited the ox-LDL induced increase in SIRT3 pro-
tein level (Fig. 5A). Inversely related to the protein level of SIRT3,
ALDH2 acetylation, as indicated by acetyl lysine was decreased by
ox-LDL and this effect was prevented by PARP inhibition (Fig. 5B).
3.6. Selective knockdown of SIRT3 with siRNA preserved ALDH2 activity
in ox-LDL treated HAECs
To conﬁrm the role of SIRT3 in ALDH2 dehydrogenase activity,
SIRT3 was knocked down with siRNA. Compared with nontransfected
cells and nonsense siRNA-transfected cells, SIRT3 siRNA signiﬁcantly
inhibited SIRT3 protein expression (Fig. 6A), and effectively increased
ALDH2 acetylation in ox-LDL treated HAECs compared with ox-LDL
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(Fig. 6B). In accordance with previous studies [16,17], the activity of
ALDH2 was preserved by SIRT3 inhibition in ox-LDL treated HAECs
(Fig. 6C). The protein level of ALDH2 was still not altered by the selec-
tive knockdown of SIRT3 (Fig. 6D).
3.7. ALDH2 activity was preserved by PARP inhibition in ischemia–
reperfusion injured heart
To further conﬁrm the role of PARP inhibition in ALDH2 dehydro-
genase activity in vivo, we used a rat cardiac ischemia–reperfusion
injury model. ROS play an important role in producing lethal cell inju-
ry during cardiac ischemia–reperfusion [24], and PARP is activated in
cardiac tissue following ischemia–reperfusion [25]. Using DPQ, PARP
inhibition signiﬁcantly reduced the myocardial infarct size compared
with IR heart in our study (Fig. 7A). Ischemia–reperfusion induced a
marked increase in PAR expression compared with the control
group and PARP inhibition effectively prevented PAR production in
IR hearts (Fig. 7B). Inversely related to PARP activation, ALDH2
dehydrogenase activity was inhibited in ischemic myocardial areas
(Fig. 7C). PARP inhibition was also found to be able to preserve
ALDH2 activity in ischemia–reperfusion hearts (Fig. 7C) without any
change in the protein level of ALDH2 (Fig. 7D). Moreover, ischemia–
reperfusion increased SIRT3 expression which was prevented by
PARP inhibition in rat hearts (Fig. 7D). In contrast to SIRT3 expression,
ALDH2 acetylation was decreased by ischemia–reperfusion injury and
preserved by PARP inhibition (Fig. 7E).
4. Discussion
In the present study, we demonstrated that ox-LDL treatment and
ischemia–reperfusion injury markedly decreased ALDH2 dehydroge-
nase activity and PARP inhibition partly restored ALDH2 activity in
HAECs and rat hearts. Using SIRT3 siRNA, SIRT3 was found to contrib-
ute to the inhibitory effect of PARP activation on ALDH2 dehydroge-
nase activity by regulating ALDH2 acetylation.Fig. 6. Knockdown of SIRT3 with siRNA prevented the ox-LDL induced decrease in ALDH2
B, SIRT3 knockdown increased ALDH2 acetylation. C, ALDH2 activity was preserved in ox-LD
determinations in 5 separate experiments. *Pb0.01 vs control; #Pb0.01 vs ox-LDL treated gALDH2 has two types of enzyme activity: dehydrogenase activity,
through which ALDH2 plays a critical role in aldehyde and ethanol
metabolism [14,26–28], and esterase activity, which is related to the
bioactivation of nitroglycerin [29] and nitrate tolerance [30]. Given
the central role of lipid peroxidation in atherosclerosis and other
heart diseases, the effects of aldehydes are likely to be particularly
important in cardiovascular diseases [4]. Therefore, identifying the
pathway regulating ALDH2 dehydrogenase activity beneﬁts the treat-
ment of cardiovascular diseases. Previous studies have shown that
ALDH2 activity is inhibited by ROS [18,31]. In the present study, we
found that ox-LDL and ischemia–reperfusion injury decreased
ALDH2 dehydrogenase activity.
The protein expression of ALDH2 may be downregulated by ROS in
nitrate tolerance or diabetic rats [11,32]. However, ALDH2protein levels
are unchanged or changed by a small amount after exposure to alcohol
or hepatic ischemia–reperfusion injury [6,16]. In the present study, we
found that the protein level of ALDH2 was unchanged by ox-LDL treat-
ment inHAECs and ischemia–reperfusion injury in rat hearts. Therefore,
the inhibitory effect of ox-LDL treatment and ischemia–reperfusion in-
jury on ALDH2 dehydrogenase activity was not mediated by the
downregulation of ALDH2 protein but possibly by post-translational
modiﬁcations.
PARP is a DNA repair enzyme that is sensitive to and activated by
both single- and double-stranded DNA breaks [19]. Ox-LDL and
ischemia–reperfusion injury increased ROS, which could damage DNA
and consequently activate PARP [25]. As PARP overactivation consumes
cellular NAD+, we tested whether PARP activation plays a role in
inhibiting ALDH2 dehydrogenase activity. We found that PARP inhibi-
tion with DPQ partly restored ALDH2 dehydrogenase activity in
ox-LDL treated HAECs. Although cellular NAD+ was decreased, the
level of mitochondrial NAD+ was not changed by PARP activation
[23,33]. In the present study, we also found that the mitochondrial
NAD+ level was not changed by ox-LDL stimulation or PARP inhibition.
As ALDH2 is a mitochondrial NAD+-dependent enzyme, the effect of
PARP on ALDH2 dehydrogenase activity should not be mediated
throughmitochondrial NAD+.Moreover,we found that the ALDH2pro-
tein level was not altered by PARP inhibition. These ﬁndings furtheractivity. A, The protein expression of SIRT3 was effectively decreased by SIRT3 siRNA.
L treated HAECs by SIRT3 inhibition. The data represent means of 3 samples of duplicate
roup. D, The protein expression of ALDH2 was not changed by knockdown of SIRT3.
Fig. 7. PARP inhibition preserved ALDH2 dehydrogenase activity during ischemia reperfusion-injury in rat hearts. A, Sections of rat hearts were stained with Evans blue and TTC to
visualize the myocardial area at risk (AAR) and infract area. Myocardial infarct size was quantitatively analyzed. n=5. B, PAR in the ischemic myocardial area was immunostained
and quantiﬁed. Bar=50 μm. n=5. C, The ALDH2 dehydrogenase activity of the ischemic myocardial area was determined. D and E, ALDH2, SIRT3 and the lysine acetylation of
ALDH2 were examined with immunoblotting. The blot represents the results of 5 samples of duplicate determinations. *Pb0.05 vs control group; **Pb0.01 vs control group;
#Pb0.05 vs IR group; ##Pb0.01 vs IR group.
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ALDH2 dehydrogenase activity not through protein expression but by
protein modiﬁcation.
ALDH2 protein can be modiﬁed by various forms of post-
translational modiﬁcations, including oxidation, S-nitrosylation, phos-
phorylation, nitration, acetylation, glycosylation, and adduct formation
[6]. Recently, deacetylation by SIRT3 has emerged as an important
post-translational modiﬁcation regulating the function of many mito-
chondrial proteins [34,35]. The lysine of ALDH2 can also be acetylated
[36]. The acetylation level of ALDH2 can be modiﬁed by SIRT3 and a
reduction in ALDH2 deacetylation could maintain ALDH2 dehydroge-
nase activity [16,17]. In primary cultured mouse cortical neurons,
PARP activation mediated NAD+ depletion and subsequently increasedinmitochondrial SIRT3 [33]. Similarly, we found that PARP activation by
ox-LDL signiﬁcantly decreased the cellular NAD+ level and increased
SIRT3 expression, which led to a decrease in ALDH2 acetylation in
HAECs. Furthermore, PARP inhibition prevented SIRT3 upregulation
and preserved ALDH2 acetylation. To conﬁrm the role of deacetylation
by SIRT3 on ALDH2 dehydrogenase activity, SIRT3 was selectively
knocked down with siRNA in ox-LDL treated HAECs and we found
that SIRT3 could affect ALDH2 dehydrogenase activity by regulating
the lysine acetylation of ALDH2. The in vivo study also indicated that
PARP overactivation inhibited ALDH2 dehydrogenase activity and
increased SIRT3 expression in ischemia–reperfusion rat hearts. Consis-
tent with the results from in vitro study, PARP inhibition restored
ALDH2 activity, prevented the increase in SIRT3 expression and
486 S. Wei et al. / Biochimica et Biophysica Acta 1833 (2013) 479–486subsequently maintained the acetylation level of ALDH2 in ischemia–
reperfusion rat hearts. Therefore, PARPmight affect ALDH2 dehydroge-
nase activity through the SIRT3 pathway, which regulates ALDH2
acetylation.
In conclusion, our study demonstrated that ox-LDL and ischemia–
reperfusion injury effectively decreased ALDH2 dehydrogenase activity
and PARP inhibition preserved the dehydrogenase activity of ALDH2 by
preventing an increase in SIRT3 expression and maintaining the acety-
lation level of ALDH2.
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.bbamcr.2012.11.007.Acknowledgments
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